New IPF drug candidate enters first human safety trial
NCT ID NCT07593690
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new tablet called HW241045 in 102 healthy volunteers to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a lung-scarring disease. The study is randomized, double-blind, and placebo-controlled, meaning some participants get a dummy pill. It is not yet testing if the drug works against the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HW241045 tablets
What this could lead to
If this early safety trial succeeds, it could pave the way for a new treatment to control idiopathic pulmonary fibrosis, a serious lung disease.
What could go wrong
This is a very early Phase 1 study in healthy people, not patients. It only tests safety and dosing, not whether the drug works for IPF. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Shandong First Medical University(Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••